Randomized Trialhigh evidence
Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.
The New England journal of medicine·November 7, 2026·PMID 43001751
Why it mattersInterleukin-6 is a key inflammatory mediator implicated in atherosclerosis, and prior biomarker and genetic data suggested that lowering IL-6 could reduce cardiovascular events. This large trial directly tests that hypothesis in a high-risk population with elevated CRP and CKD, providing definitive evidence that IL-6 neutralization with ziltivekimab does not improve cardiovascular outcomes despite robust biomarker suppression.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled